GlobeNewswire by notified

New Peer-Reviewed Paper Validates General Fusion Code Accelerating Commercial Power Plant Design

Share

RICHMOND, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- General Fusion is advancing the design of its Magnetized Target Fusion (MTF) commercial power plant with proprietary simulation code now validated in a peer-reviewed scientific paper. General Fusion is unique in its ability to iterate nimbly. Since 2002, the company has built and tested dozens of complex prototypes. Now, it can move even faster. The code, introduced in a new paper in Physics of Fluids, helps General Fusion to rapidly model its game-changing liquid metal liner in a commercial machine. General Fusion completes simulations in a minute on a single computer that otherwise would take hours or weeks. No other programming available on the market can achieve this result today.

The code is a key component of General Fusion’s Integrated System Model (ISM). With ISM, the company quickly tests different designs to determine the best machine configuration for a practical and economical power plant. Known as ISM-hydrodynamics (ISM-hydro), the validated code predicts the motion of General Fusion’s proprietary liquid metal liner as it is mechanically compressed by an array of pistons. As the company optimizes the power plant configuration, it uses the code to understand the performance of the liner in a commercial machine. General Fusion’s MTF approach to compressing liquid metal around the plasma to create fusion energy is unique in the world. It is the only fusion technology that addresses the major barriers to commercialization, including material degradation, fuel production, energy capture, and cost barriers.

“Our proprietary Integrated System Model is an excellent example of why the time for fusion is now. We are designing and building fusion machines faster than ever before,” said Greg Twinney, CEO, General Fusion. “This new paper in Physics of Fluids highlights our team’s incredible work in developing the first-of-a-kind tools we need to deliver commercial fusion in the next decade. We are making significant progress every day.”

ISM-hydro is part of a broader integrated system model, which plays a crucial role in analyzing experimental data, operating sub-scale test beds, and optimizing the design of General Fusion’s ground-breaking Lawson Machine 26 (LM26). LM26 shortens the technical jump between General Fusion’s next near-commercial machine and a commercial pilot plant. As a result, the company is fast-tracking its path to provide commercial fusion energy to the grid by the early to mid-2030s.

Quick Facts:

  • General Fusion’s Magnetized Target Fusion uniquely sidesteps challenges to commercialization that other technologies face. The game-changer is a proprietary liquid metal liner in the commercial fusion machine that is mechanically compressed by an array of pistons.
  • This enables General Fusion to create fusion conditions in short pulses, rather than creating a sustained reaction, while protecting the machine’s vessel, extracting heat, and re-breeding fuel. Additionally, General Fusion’s design does not require large superconducting magnets or expensive lasers.
  • Recently published peer-reviewed scientific results confirm General Fusion’s proprietary liquid metal compression technology scalable to a commercial machine. The results were published in Fusion Engineering and Design after the team completed over 1,000 liquid compression experiments.
  • General Fusion’s new MTF demonstration, LM26, is designed to reach fusion conditions of over 100 million degrees Celsius by 2025. It will progress towards scientific breakeven equivalent by 2026.
  • The MTF demonstration will integrate the company’s operational plasma injector with a simplified compression system. The plasma injector has already achieved the temperature and magnetic confinement times required by the new machine.

About General Fusion 
General Fusion is pursuing a fast and practical approach to commercial fusion energy and is headquartered in Richmond, B.C., Canada. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com.

General Fusion Media Relations
media@generalfusion.com
+1-866-904-0995

Follow General Fusion
twitter.com/generalfusion
instagram.com/generalfusion
linkedin.com/company/general-fusion
facebook.com/generalfusion
youtube.com/c/GeneralFusionInc

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release

VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available

DBV Technologies Announces Results of its 2024 Combined General Meeting16.5.2024 22:30:00 CEST | Press release

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/. About DBV Technologies DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with sign

Clean Motion AB delårsredogörelse för januari-mars 202416.5.2024 22:10:00 CEST | Pressemelding

Elfordonstillverkaren Clean Motion AB presenterar sin delårsrapport för januari-mars 2024. Bolaget redovisar en försäljning på 38 (45) TSEK och ett rörelseresultat exklusive avskrivningar (EBITDA) på -2 949 (-1 825) TSEK. Bolaget meddelar även att ett licensavtal är tecknat för tillverkning av Zbee i Indien samt att deras nya produktionslokal för EVIG i Jonsered nu är godkänd. Sofia Haby, VD kommenterar; ”Vi har jobbat intensivt under kvartalet med både typgodkännande-processen och flytt till nya lokaler. Kvartalet har präglats av de förseningar som vi drabbats av med vårt typgodkännande, vilket förhindrat försäljning i Europa. Jag kan nu med glädje meddela att det mest kritiska testet blev godkänt igår kväll! Under de senaste månaderna har vi jobbat med att färdigställa vår nya produktionslokal i Jonsered. Jag är övertygad om att vi genom att samla alla resurser under ett tak, kommer att åstadkomma stora effektivitetsförbättringar. Teamet har arbetat dedikerat med att säkerställa en s

Galapagos creates new subscription right plans16.5.2024 22:01:00 CEST | Press release

Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH16.5.2024 22:00:00 CEST | Press release

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.The DMC review confirms the good safety profile of lanifibranor. Daix (France), Long Island City (New York, United States), May 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepa

HiddenA line styled icon from Orion Icon Library.Eye